相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。326 Assessment of the Efficacy and Safety of Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis
Scott D. Lee et al.
GASTROENTEROLOGY (2015)
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission
Alessandro Armuzzi et al.
INFLAMMATORY BOWEL DISEASES (2013)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
Laurent Peyrin-Biroulet et al.
GUT (2012)
Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and-2 extension studies
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2012)
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial
David Laharie et al.
LANCET (2012)
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab
C. Taxonera et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response
Geert R. D'Haens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Current misunderstandings in the management of ulcerative colitis
Thomas Ochsenkuhn et al.
GUT (2011)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
N. Gies et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization
Abderrahim Oussalah et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
C. H. Seow et al.
GUT (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Medical Management of Ulcerative Colitis
Gerhard Rogler
DIGESTIVE DISEASES (2009)
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
I. Arijs et al.
GUT (2009)
Increased Efficacy of Delayed-Release Mesalamine 4.8g/D (800mg Tablet) in Patients Previously Diagnosed with Ulcerative Colitis (UC)
William J. Sandborn et al.
GASTROENTEROLOGY (2009)
Long-term outcome after infliximab for refractory ulcerative colitis
Marc Ferrante et al.
JOURNAL OF CROHNS & COLITIS (2008)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis:: A randomized, placebo-controlled study
G Järnerot et al.
GASTROENTEROLOGY (2005)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
分享论文
